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Zika virus pathogenesis in rhesus macaques is
unaffected by pre-existing immunity to dengue
virus
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Zika virus (ZIKV) is a re-emerging virus that has recently spread into dengue virus (DENV)
endemic regions and cross-reactive antibodies (Abs) could potentially affect ZIKV patho-
genesis. Using DENV-immune serum, it has been shown in vitro that antibody-dependent
enhancement (ADE) of ZIKV infection can occur. Here we study the effects of pre-existing
DENV immunity on ZIKV infection in vivo. We infect two cohorts of rhesus macaques with
ZIKV; one cohort has been exposed to DENV 2.8 years earlier and a second control cohort is
naı¨ve to flaviviral infection. Our results, while confirming ADE in vitro, suggest that pre-
existing DENV immunity does not result in more severe ZIKV disease. Rather our results
show a reduction in the number of days of ZIKV viremia compared to naı¨ve macaques and
that the previous exposure to DENV may result in modulation of the immune response
without resulting in enhancement of ZIKV pathogenesis.
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Z
ika virus (ZIKV), a member of the Flaviviridae family, is a
re-emerging mosquito-borne virus. It was discovered in
Uganda (1947) and has been reported in the Americas
since 2014 with a major outbreak in Brazil starting in 2015
(refs 1,2). Since then, it has spread to at least 38 countries in
South America, Central America and the Caribbean islands1.
ZIKV has been associated with neurological sequelae
Guillain–Barre´ syndrome (GBS) in adults and microcephaly in
newborns. Because of the explosive outbreak in South America
and fast spreading in other parts of the world, the World Health
Organization (WHO) declared ZIKV a serious public health
emergency in February 2016 (ref. 3). Of particular concern is that
ZIKV infection virulently occurs in areas previously exposed to
dengue virus (DENV). ZIKV and DENV belong to the same virus
family, and are transmitted mainly by the same mosquito vector
(Aedes aegypti). Both viruses are closely related, with a homology
of 51–54% in the amino acid sequence of their envelope proteins4.
DENV occurs in four serotypes in nature. While primary
infection with one serotype confers life-long homotypic
immunity to its own future infections, a heterotypic secondary
infection promotes more severe clinical manifestations leading
to DENV-hemorrhagic fever and DENV-shock syndrome
(DHF/DSS)5,6. This has been explained by different
mechanisms including the antibody-dependent enhancement
(ADE) hypothesis7–9. This mechanism suggests that antibodies
(Abs), generated in response to the primary infection with
DENV, are not of sufficient concentration or avidity to neutralize
a secondary infection with DENV of a different serotype, and
may even facilitate its replication. ADE has been confirmed and
demonstrated to occur in vitro, and has also been shown to drive
higher loads of DENV in animal models10–12. Another
mechanism proposed for the development of DHF/DSS is the
production of cross-reactive T-cell clones during the primary
infection13,14. Recently, different groups have shown that
serum from DENV-immune subjects can induce ZIKV ADE
in vitro15–17. Coincidentally, the only published study to date that
provides evidence for ZIKV infection causing GBS used a cohort
of 42 cases in French Polynesia of whom, strikingly, 95% had pre-
existing DENV immunity18. The incidence of microcephaly and
other fetus abnormalities have been reported with varied
frequencies in two different countries with ZIKV outbreaks.
The two published epidemiological studies addressing this
situation are a prospective cohort study from Brazil19 and a
retrospective study in French Polynesia20. The Brazilian cohort
showed that 29% of women with ZIKV infection at any time
during pregnancy had abnormalities in prenatal ultrasonography,
while the French Polynesia study suggested that only 1% of
fetuses and infants from women who had ZIKV infection during
the first trimester of pregnancy developed microcephaly. These
and other observations have stimulated discussion and raised
questions about the role of pre-existing flavivirus immunity in
ZIKV pathogenesis especially during pregnancy21,22.
The interval between primary and secondary DENV infection is
considered to be critical in determining disease severity7,23–25.
Heterotypic immunity can be protective to new serotypes for up to
6 months. Enhanced disease is, typically, observed when people are
exposed to second infections 12 months or more after a primary
infection. Here we study how waning DENV immunity (humoral or
cellular) affects ZIKV disease. Using a cohort of macaques that were
experimentally infected with DENV 2.8 years earlier, we show that
DENV immunity does not enhance ZIKV pathogenesis in primates.
Results
DENV-immune serum induces ADE of ZIKV in vitro. Two
groups with four macaques in each group were infected with
DENV-1 or DENV-2. The animals were bled at 30 and 60 days
and at 1, 1.5 and 2.5 years after DENV infection. To determine
whether sera from DENV-immune macaques were able to
enhance ZIKV infection in vitro, we performed an ADE assay on
K562 cells. Sera collected from four DENV-immune macaques
(two DENV-1 and two DENV-2 infected animals) collected 2.5
years after infection and sera from four flavivirus-naı¨ve animals
were used for the ADE assays. In the presence of naı¨ve sera, ZIKV
strain H/PF/2013 infected o1% of K562 cells (Fig. 1). Con-
valescent sera from DENV-immune macaques led to a substantial
enhancement of ZIKV infection at low serum dilutions, ranging
from 10 to 20% (Fig. 1). One DENV-2 pre-exposed animal
(MA071, see below) showed the highest enhancement (420%).
These results confirm that previous exposure to DENV and the
presence of DENV-immune serum induces ADE of ZIKV
in vitro.
Rhesus macaque cohorts. In 2013, we infected rhesus macaques
(Macaca mulatta) with 5 106 p.f.u. subcutaneously (s.c.) of
DENV-1, Western Pacific 74, or DENV-2, New Guinea 44
(cohort 1 in Fig. 2). Both groups in this cohort were sequentially
bled at 30 and 60 days and at 1, 1.5 and 2.5 years post-DENV
infection. After that two macaques from each group were chal-
lenged with ZIKV for this proof-of-concept study 2.8 years after
DENV infection. In addition, this work includes a second cohort
(cohort 2) with four flavivirus-naı¨ve macaques as control group.
Prior to ZIKV infection all eight macaques were subjected to a
forty-day quarantine period.
Clinical status of macaques before and after ZIKV exposure.
ZIKV-infected macaques were regularly evaluated for evidence of
disease or injury. No significant variations in weight (Fig. 3a) and
external or rectal temperature (Fig. 3b,c) were detected. External
temperature reading was above 38.8 C only for one naı¨ve animal
(BS02) (Fig. 3b). Complete blood count (CBC) and chemistries
were evaluated for all eight macaques on baseline and on days 7,
15 and 30 post infection (p.i.). White blood cell (WBC) counts
dropped at 7 days post infection (d.p.i.) in both cohorts of
macaques and returned to baseline levels by day 15 p.i. (Fig. 3d).
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Figure 1 | In vitro ADE of ZIKV infection by macaque DENV-immune
antisera in K-562 cells. Sera from four DENV-immune (two per serotype)
and four naı¨ve macaques were serially diluted and incubated with ZIKV
strain H/PF/2013 at a multiplicity of infection (MOI) of 1. K-562 cells were
added and incubated for 22 h, and the percentage of ZIKV-infected cells
were determined by flow cytometry after intracellular staining with
E-specific mAb 4G2 conjugated to Alexa-488. DENV-1 immune macaques
are in blue, DENV-2 immune ones in magenta, and naı¨ve ones in black. Data
are representative of the average of triplicate samples per concentration in
one experiment. Statistically significant differences among groups were
calculated by two-way ANOVA using Bonferroni’s multiple comparisons
test.
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Absolute numbers of lymphocytes (LYM), neutrophils (NEU)
and monocytes (MON) were also decreased at 7 d.p.i. both in
naı¨ve and pre-exposed macaques (Fig. 3e–g). However, compared
to their baseline values, only the drop in the absolute NEU
numbers at 7 d.p.i. in DENV-immune macaques was statistically
significant (Po0.01) (Fig. 3f). The percentage of WBC also
changed after infection (Supplementary Fig. 1). The per cent of
MON showed a significant increase in DENV-immune macaques
by day 7 p.i. compared to their baseline values (Po0.05)
(Supplementary Fig. 1). Platelet counts remained constant in
both cohorts (Fig. 3h). In all macaques, liver enzymes alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)
levels were elevated at 7 d.p.i. when compared to baseline
(Fig. 3i,j). Particularly, ALT showed a non-significant but strong
trend towards higher values by day 7 p.i. in naı¨ve macaques
compared to both DENV-1 and 2-immune macaques. Values
returned to baseline by day 15 (Fig. 3i,j). No apparent clinical
signs were noticeable in seven of eight macaques. One of the four
DENV-immune macaques (BS14) developed a nonpruritic skin
rash (Supplementary Note 1, Supplementary Fig. 2).
Immune profile of cohorts before ZIKV infection. We
measured the levels of binding and neutralizing Abs (Nabs) to
DENV and ZIKV before challenging the animals with ZIKV.
All DENV-immune macaques showed an increase of DENV IgG
titres (Supplementary Fig. 3a). Reading of optical density
(OD, 450 nm) that measures the level of IgG remained high up to
1 year after DENV infection, and declined slightly by 2.5 years
(by the time the sample was collected prior to ZIKV infection) in
all but two macaques infected with DENV-1 or DENV-2 (BP71
and MA071, respectively). All macaques were negative for DENV
IgM (Supplementary Fig. 3b). DENV-naı¨ve macaques were
negative for both DENV IgM or IgG (Supplementary Fig. 3b,c)
and for ZIKV-IgM (Supplementary Fig. 3f). Macaques in group 1
(DENV-1 immune) showed no reactivity against ZIKV-NS1
protein. From this group, two were selected for infection with
ZIKV (BS14 and BP71). However, macaques pre-exposed to
DENV-2 (n¼ 4), showed an increase of ZIKV-NS1 IgG at days
30 and 60 after DENV infection. Three out of four macaques in
group 2 (DENV-2 immune) still had detectable cross-reactive IgG
to ZIKV-NS1 protein at 1 and 2.5 years p.i. (Supplementary
Fig. 3d). From group 2, one macaque with high cross-reactivity
(MA071) and one animal with undetectable levels of IgG to
ZIKV-NS1 protein (BS02) at the time of the challenge, were
selected for infection with ZIKV. As shown in Table 1, before
ZIKV challenge, DENV-pre-exposed macaques had Abs that
neutralized one or more DENV serotypes but not to ZIKV. In
summary, DENV-infected animals had variable levels of IgG that
cross-reacted with ZIKV antigens but the Nabs induced by
DENV infections did not cross-neutralize ZIKV.
Immune profile after ZIKV infection. Thirty days after ZIKV
infection, all exposed macaques showed a significant increase
in the cross-reacting anti-DENV IgG value. The values of IgG
anti-ZIKV NS1 protein were also enhanced in both cohorts
(Supplementary Fig. 3e). All macaques developed IgM to ZIKV
by 10 d.p.i. (Supplementary Fig. 3f). IgM titres peaked by day 15
and declined to basal levels by day 30 p.i. The naı¨ve macaques
challenged with ZIKV had high levels of Abs that neutralized
ZIKV and also lower levels of DENV cross-neutralizing Abs that
declined between day 30 and 60 after infection (Table 1).
The DENV-immune macaques challenged with ZIKV developed
high levels of ZIKV neutralizing antibodies as well as a boost in
their DENV Nab titres (Table 1). In most of pre-immune
macaques, the DENV and to a lesser extent the ZIKV neutralizing
antibodies declined between days 30 and 60 p.i. (Table 1).
The hierarchy of NAb titres observed 30 days after ZIKV
infection was different in the two cohorts and also different
for the two groups exposed to different DENV serotypes. For
naı¨ve macaques it was ZIKV4D24D14D34D4, for DENV-1
ZIKV4D14D24D44D3 and for DENV-2 immune macaques
ZIKV4D24D34D14D4.
To further characterize the degree of Ab cross reactivity between
DENV and ZIKV, we measured the binding of antibodies in the
sera from the two cohorts before and after ZIKV infection to the
whole ZIKA virus antigen using IgG ELISA. At baseline, all DENV-
immune macaques showed cross-reactivity with titres up to a
dilution of 1 10 log3 while naı¨ve macaques were essentially
negative (Fig. 4a). For samples collected 30 d.p.i, naı¨ve macaques
had ZIKV-specific IgG up to a dilution of 1 10 log3 and the
DENV-immune cohort showed significantly higher values in the
first two dilutions (Po0.05) when compared to naı¨ve macaques
(Fig. 4b). DENV-immune macaques also showed a statistically
significant increase in the OD values while measuring IgG endpoint
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Figure 2 | Experimental design of ZIKV infection in DENV-immune and naı¨ve macaques. Two cohorts of rhesus macaques (Macaca mulatta) were used.
Cohort 1 was composed of four macaques previously infected with DENV (5 106 p.f.u., s.c.) in 2013. Two macaques were from a group (n¼4) infected
with DENV-1 Western Pacific 74 (WP74) strain (BS14 and BP71), and the other two macaques from a group (n¼4) infected with DENV-2 New Guinea 44
(NGC44) strain (MA071 and BS02). Cohort 1 in 2013 was sequentially bled at baseline, 30, 60 d.p.i., 1.5 and 2.5 years post DENV infection. Macaques in
cohort 1 include one with high and one with low NAb titres against DENV-1 or DENV-2 (Supplementary Fig. 3). Cohort 2 contains four flavivirus-naı¨ve
macaques as control (5K6, CB52, 2K2 and 6N1). Macaques in both cohorts matched in age and sex. Cohorts were bled 30 days (Baseline) prior to infecting
with ZIKV, and in August 1, 2016 they were infected with ZIKV (1 106 p.f.u., s.c.) H/PF/2013 strain. Afterwards, all macaques were first bled from 1 to 10
d.p.i., and then on 15, 30 and 60 d.p.i. Furthermore, saliva and urine samples were also collected at the same timepoints. ZIKV infection was performed 2.8
years after DENV infection.
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titres for binding to ZIKV when compared to their own OD
baseline values in the first two dilutions (Po0.05 and Po0.01). One
of four macaques (MA071, DENV-2-exposed) showed the highest
OD for serum dilution up to 1 10 log5. Remarkably, it is the same
animal that showed cross reactivity with ZIKV-NS1 protein and the
highest DENV NAb titres prior to the ZIKV infection. Altogether,
these results confirm the contribution of pre-existing DENV-
immunity to the expansion of cross-reacting ZIKV-IgG levels early
after ZIKV infection in macaques.
Viremia in serum. To determine if pre-existing DENV immunity
enhances ZIKV replication in primates, we measured ZIKV vir-
emia using quantitative real-time reverse transcription PCR
(qRT-PCR). Viral RNA (vRNA) detection was consistent in both
groups during the first 4 days after infection (Table 2, Fig. 5). On
day 5 p.i., three of four naı¨ve versus one of four DENV-immune
macaques had detectable vRNA. On day 6 this ratio changed to
two of four of naı¨ve and three of four DENV-immune macaques
with detectable viremia. DENV-immune macaques showed a
trend with a shorter duration of viremia with only two out of four
macaques having detectable levels of vRNA during the period of
7–15 d.p.i. In comparison, all four of naı¨ve macaques had
detectable vRNA levels in at least one day within the 7–15 d.p.i.
By day 30 p.i., only two of the four DENV immune compared to
all four naı¨ve macaques had detectable ZIKV RNA. In general,
DENV-immune macaques showed less viremia days compared to
naı¨ve macaques (25 versus 31 days, respectively). Of relevance to
this study, the pre-challenge neutralization titres to DENV do not
correlate with the peak or magnitude of ZIKV viremia (Table 1).
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Figure 3 | Vital signs and clinical status of macaques before and after ZIKV infection. (a) Weight expressed in kilograms (kg). (b) Corporal temperature
(in Celsius) measured using an infrared device. (c) Rectal temperature (in Celsius) was also measured. (d–g) Cell subsets: white blood cell (WBC),
lymphocyte (LYM), neutrophil (NEU) and monocyte (MON) kinetics obtained from complete blood cell (CBC) counts (106 cells per ml) at baseline and on
days 7 and 15 p.i. in absolute numbers. Comparison of absolute NEU numbers within cohorts at day 7 related to their own baseline values was performed
using a two-tailed unpaired t-test with Sidak–Bonferroni correction (Po0.01). (h–j) Levels of platelets (106 PLT per ml), Alanine Aminotransferase (ALT)
and Aspartate Aminotransferase (AST) at baseline, 7 and 15 d.p.i. In all panels, the DENV-1 immune macaques are in blue, DENV-2 immune ones in
magenta, and naı¨ve ones in black.
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ZIKV in urine and saliva. ZIKV vRNA was detected using qRT-
PCR in the urine of macaques in both groups. However, the
vRNA detection was transient throughout the period of 1–30
d.p.i. and considerably lower when compared to titres detected in
the serum (Supplementary Table 1). Amplification of vRNA
was observed for at least one or two days (102–104 genome
copies per ml) in all naı¨ve and DENV-immune macaques during
1–9 d.p.i. At day 15 p.i., one out of four pre-exposed macaques
had detectable vRNA, and at day 17 one naı¨ve and one pre-
exposed macaques still had detectable vRNA. From day 19 to day
Table 1 | Neutralizing titres against DENV and ZIKV before and after 30 and 60 days of ZIKV infection.
RM ID DENV
exposure
history
PRNT/FRNT60 titre 30 days before
ZIKV infection
PRNT/FRNT60 titres 30/60 days post ZIKV infection
ZIKV DENV-1 DENV-2 DENV-3 DENV-4 ZIKV DENV-1 DENV-2 DENV-3 DENV-4
Cohort 1
BS14 1 DENV-1 o1:20 1:80 1:20 o1:20 1:80 1:2,560/1:640 1:640/1:160 1:320/1:320 1:160/1:80 1:160/1:80
BP71 1 DENV-1 o1:20 1:640 1:40 1:160 1:80 1:1,280/1:640 1:2,560/1:640 1:640/1:160 1:160/1:160 1:320/1:320
MA071 1 DENV-2 o1:20 1:40 1:2,560 1:160 1:80 1:5,120/1:2,560 1:160/1:160 1:2,560/1:2,560 1:320/1:320 1:80/1:640
BS02 1 DENV-2 o1:20 o1:20 1:320 o1:20 1:20 1:1,280/1:640 1:160/1:80 1:1,280/1:2,560 1:160/1:160 1:320/1:80
Cohort 2
5K6 Naı¨ve o1:20 o1:20 o1:20 o1:20 o1:20 1:1,280/1:1,280 o1:20/o1:20 1:40/1:40 o1:20/o1:20 1:160/1:40
CB52 Naı¨ve o1:20 o1:20 o1:20 o1:20 o1:20 1:1,280/ 1:1,280 o1:20/o1:20 o1:20/o1:20 o1:20/o1:20 1:160/1:40
2K2 Naı¨ve o1:20 o1:20 o1:20 o1:20 o1:20 1:2,560/ 1:2,560 o1:20/o1:20 1:20/1:80 o1:20/o1:20 1:40/1:40
6N1 Naı¨ve o1:20 o1:20 o1:20 o1:20 o1:20 1:2,560/ 1:1,280 1:40/o1:20 1:160/1:40 1:80/o1:20 1:640/1:160
Neutralization of DENV (DENV-1 WP74, DENV-2 NGC44, DENV-3 Sleman 73 and DENV-4 Dominique) and ZIKV strain H/PF/2013 in Vero 81 cells in presence of the sera from DENV-immune or naı¨ve
macaques at baseline, 30 and 60 d.p.i. Data presented as the concentration that resulted in 60% reduction of plaque-forming units (p.f.u.) in a Focus/Plaque-Reduction Neutralization Test (FRNT60 or
PRNT60) for DENV and ZIKV, respectively.
Table 2 | ZIKV viremia of naı¨ve and DENV-immune rhesus macaques.
Viremia (Log10 genome copies per ml) days post-ZIKV infectionRM ID DENV exposure history
1 2 3 4 5 6 7 8 9 10 15 30
Total days
Cohort 1
BS14 1 DENV-1 7.2 7.3 6.4 3.6 ND ND ND ND ND ND ND 2.9
BP71 1 DENV-1 6.0 7.1 6.5 4.0 ND 3.2 3.3 ND ND ND ND ND
MA071 1 DENV-2 6.7 7.6 7.0 5.5 3.3 3.0 ND 2.9 ND ND 2.4 2.7
BS02 1 DENV-2 6.5 7.3 5.1 3.2 ND 3.2 ND ND ND ND ND ND 25
Cohort 2
5K6 Naı¨ve 6.5 7.0 5.8 3.8 3.5 ND ND ND ND ND 2.8 2.7
CB52 Naı¨ve 6.4 7.3 7.2 5.7 3.7 ND 2.9 ND ND ND 2.8 2.7
2K2 Naı¨ve 6.8 7.8 6.4 4.2 4.0 3.7 4.1 ND ND 3.0 ND 2.8 31
6N1 Naı¨ve 6.9 7.3 6.1 3.4 ND 2.9 ND 2.9 ND ND ND 3.0
ND, not detected.
4.0
3.5
3.0
Baseline 30 days post-infection
* *
Serum dilution (log10)
–1 –2 –3 –4 –5 –6
Serum dilution (log10)
–1 –2 –3 –4 –5 –6
BS14
BP71
MA071
BS02
5K6
CB52
2K2
6N1
2.5
2.0
O
D 
49
2
1.5
1.0
0.5
0.0
4.0
3.5
3.0
2.5
2.0
O
D 
49
2
1.5
1.0
0.5
0.0
a b
Figure 4 | DENV-immune serum cross-reacts with ZIKV. (a) Binding of baseline samples from the naı¨ve (black circles) and the DENV-immune macaques
(blue and magenta symbols for DENV-1 and DENV-2 immune macaques, respectively) assayed in six concentrations of serum and expressed as OD values
at 492 nm. (b) Binding of samples collected 30 d.p.i. is represented as in a. In the first two-endpoints, serum from previous immunity to DENV resulted in
significantly higher OD values (Po0.01 and Po0.05). Data are representative of duplicate samples per concentration in one experiment. Comparison of
ZIKV IgG titres, expressed as OD values, within cohorts related to their own baseline values was performed using a two-tailed unpaired t-test with Sidak–
Bonferroni correction (*Po0.05).
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30 p.i. vRNA was not detectable in any animal. In addition to the
samples that allowed clear detection of amplification of vRNA,
there were several other samples that were highly suspicious for
the presence of ZIKV. Although the vRNA amplification under
the detection limit cannot be said as positive, we consider these
samples as highly suspicious for containing ZIKV vRNA because
they had positive amplification curves in terms of shapes and
behaviour when compared to negative non-amplification curves
(Supplementary Table 1). Within the limits of detection of our
assays (up to 500 genome copies per ml), there was no amplifi-
cation of vRNA in saliva.
Immune cell subsets phenotyping. To gain an understanding of
pre-existing DENV immunity in macaques mounting a response
against ZIKV, we analysed the cells involved in cellular immunity.
Compared to the basal level, the frequency of activated B cells
(CD20þ /CD3 /CD14 /CD69þ ) was statistically higher in the
naı¨ve cohort at 24 and 48 h (Po0.05) and 10 d.p.i. (Po0.01)
with a significant decrease by day 7 p.i. (Po0.01) (Fig. 6a).
DENV-immune macaques showed a shorter pattern of early
activation. In this group, B cells were significantly activated after
24 h (Po0.05) but not at 48 h followed by a decline on day 7 p.i.
and a new peak frequency of activation on day 10 p.i. (Po0.05).
In the naı¨ve cohort, the frequency of activation of these cells
returned to baseline levels by day 15 p.i. while the pre-exposed
cohort still had a positive but non-significant trend higher
compared to their baseline levels (Fig. 6a).
While both cohorts showed activation of CD4þ T cells with
higher frequency of CD3þ /CD4þ /CD69þ compared to the
baseline levels, only naı¨ve cohort showed statistically significant
differences and longer periods of activation (Fig. 6b). In this
cohort significant high frequency of activated cells were found at
24 and 48 h and on days 10 and 15 p.i. (Po0.05, Po0.01, Po0.01
and Po0.05, respectively) with a transient decrease by day 7 p.i.
Compared to naı¨ve macaques, DENV-immune cohort showed a
limited pattern of activation with statistically significant high
frequency of CD3þ /CD4þ /CD69þ cells only at 24 and 48 h p.i.
(Po0.05) followed by a significant drop by day 7 p.i. (Po0.01),
which did not recover by day 10 p.i. (Fig. 6b). Because of that
naı¨ve macaques showed higher frequency of activated CD4þ T
cells at 48 h and on day 7 p.i. (Po0.05 and Po0.01, respectively),
when compared to DENV-immune ones, in spite of the decrease
by day 7 p.i. in both groups. Compared to baseline, naı¨ve
macaques showed a continued activation of CD8þ T cells with
significantly higher frequency of CD3þ /CD8þ /CD69þ cells at
24 and 48 h and on days 7 and 10 p.i. (Po0.01, Po0.01, Po0.05
and Po0.05, respectively) (Fig. 6c). In contrast, although
DENV-immune macaques showed a trend to increase the
frequency of these cells, the differences compared to baseline
values were not statistically significant at any measured time
point (Fig. 6c). In both cohorts activated natural killer (NK)
CD16þ cells increased at 48 h after the infection, with a decrease
in the frequency of activation by day 7 p.i., returning to baseline
level by day 15 p.i. However, differences in the frequency of
activation were not significant in any cohort (Supplementary
Fig. 4). Nevertheless, the pattern of activation of NK CD16þ
CD69þ we observed in our macaques is very similar to the
pattern previously reported for rhesus macaques of Indian
origin26.
T-cell immune response analysis. To determine if a prior
exposure to DENV impacted the ZIKV-specific functional
response from the CD8þ and CD4þ T cells we measured their
responses 30 d.p.i. of ZIKV in all eight macaques from both naı¨ve
and DENV-immune cohorts. To assess the stability of the
functional effector response we also looked at their effector
responses 60 d.p.i. in three of the naı¨ve ones where samples
available (2K2, 5K6 and CB52) and all of the four
DENV-immune (BP71, BS14, BS02 and MA071) macaques.
Figure 7 shows the percentage of CD8þ T cells from the PBMCs
isolated on 30 d.p.i. that were capable of producing IFN-g
(Fig. 7a), TNF-a (Fig. 7b) and CD107a (Fig. 7c) in response to the
listed stimuli. Figure 7d–f depicts the same effector function in
the same macaques 60 d.p.i. of ZIKV allowing to assess the
durability of such response. Unstimulated control levels for each
animal carried out on days 30 and 60 d.p.i. are shown in
Supplementary Table 2.
We first looked at the IFN-g production from the CD8þ T
cells (Fig. 7a) 30 d.p.i. of ZIKV. We detected IFN-g in the CD8þ
T cells from two of the DENV-immune macaques BP71 (0.56%)
and MA071 (0.35%) in response to whole ZIKV stimulation
(Fig. 7a). These macaques maintained this response until 60 d.p.i.
(BP71, 0.42% and MA071, 0.24%) (Fig. 7d). We did not, however,
detect a CD8þ T-cell response to the DENV Envelope (E)
peptide pool in any of the immune macaques suggesting that their
response was not directed towards the DENV envelope. Two
naı¨ve (5K6, 0.32% and 6N1, 0.41%) and one pre-exposed (BS14,
0.62%) had detectable levels of IFN-g following ZIKV-E peptide
pool stimulation on day 30 p.i. However, by day 60, the peptide
specific responses from 5K6 (0.06%) and BS14 (0%) were below
the limit of detection. Three of the four naı¨ve 2K2 (0.59%), 6N1
(0.71%), and CB52 (0.41%) and three of the four immune BP71
(0.53%), BS14 (0.46%), and MA071 (0.52%) macaques had
detectable IFN-g response to ZIKV infection on day 30; and on
day 60 we were still able to detect a small response in one naı¨ve
2K2 (0.31%) and two immune BP71 (0.34%) and MA071 (0.42%)
macaques.
We focused next on TNF-a production from the CD8þ T cells
(Fig. 7b,e). We detected a robust TNF-a response to ZIKV-E
peptide pool at 30 d.p.i. in three naı¨ve macaques 2K2 (6.12%),
5K6 (1.7%), and 6N1 (2.7%) and in a single immune animal BS14
(3.7%). By day 60 p.i. the amount of TNF-a detected in the
antigen-specific CD8þ T cells was considerably diminished with
only a single DENV-immune animal BS14 (0.42%) having
detectable TNF-a level above the background (Fig. 7e). We
detected elevated TNF-a in two naı¨ve, 2K2 (3.5%), and 6N1
(3.0%), and one immune BS14 (3.8%) animal, in response to the
ZIKV NS peptide pool; however, we were unable to detect any
response above background by 60 d.p.i. of ZIKV. Interestingly,
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unlike our peptide stimulation assay, viral infection did not
appear to stimulate CD8þ or CD4þ T cells to make TNF-a
above background levels in any of the assay conditions.
CD107a production also highlight a strong antigen-specific
response in the CD8þ T cells, and we were able to detect it 30
d.p.i. of ZIKV, which was still present at 60 d.p.i. (Fig. 7c,f).
We noticed that the DENV-immune macaques appeared to have
higher percentage of CD107aþ CD8þ T cells in response to the
stimuli (to ZIKV-E, NS1 peptides, and the whole DENV) as
compared to the naı¨ve macaques suggesting that rather than
hampering the immune response, a prior DENV infection,
indeed, enhanced the ability of the CD8þ T cells to release lytic
granules in response to their cognate antigen (Fig. 7c,f).
Akin to the CD8þ T response, the ZIKV-specific CD4þ T
response did not appear to be impacted by prior DENV infection.
We detected a robust CD4þ T response in both the naı¨ve and
DENV-immune macaques 30 d.p.i of ZIKV, which decreased by
60 d.p.i. (Fig. 7g–i). Thirty days after ZIKV infection we saw a
strong polyfunctional CD4þ T-cell response, where the CD4þ T
cells from BS14 made IFN-g (0.70%), TNF-a (9.6%) and CD107a
(2%) in response to the E peptide pool stimulation (Fig. 7g–i). As
with the CD8þ T response to ZIKV or DENV infection, the
PBMCs induced IFN-g and CD107a response in both the naı¨ve
and DENV-immune macaques at 30 d.p.i. of ZIKV (Fig. 7g,i),
which decreased by 60 d.p.i. (Fig. 7j,l). However viral infection of
the PBMCs with ZIKV or DENV again failed to induce TNF-a
production (Fig. 7h,k). Nevertheless CD4þ T cells from most of
the naı¨ve and DENV-immune macaques were able to induce
ZIKV specific CD4þ T responses after ZIKV infection suggesting
that, similar to CD8þ T cells, a prior DENV infection did not
dampen the cellular immune response to ZIKV.
Cytokine profile. DENV-immune macaques showed higher
basal levels of IFN-a compared to naı¨ve macaques but they were
statistically insignificant (Fig. 8a). However, IFN-a was found to
be noticeably higher, compared to basal levels, only in naı¨ve
macaques at 24 (Po0.01), 48 (Po0.05) and 72 (Po0.05) hours
post infection (h.p.i.). One animal pre-exposed to DENV-2
(BS02) showed a significant increase at 24 h.p.i. By day 6 p.i.,
when values decreased to basal levels, naı¨ve cohort still had more
IFN-a than DENV-immune cohort (Po0.01) (Fig. 8a). In terms
of IFN-g, DENV-immune macaques showed higher basal levels
compared to naı¨ve ones (Po0.05). However, after ZIKV infection
the level of this cytokine was not increased. Only one macaque
pre-exposed to DENV-2 (BS02) had a transient surge of IFN-g 24
h.p.i. (Fig. 8b). In contrast, all naı¨ve macaques showed an early
pattern of IFN-g induction with a significant increase as early as
24 h.p.i. (Po0.05) without any other noticeable increase. In
agreement with this early peak of IFN-g, naı¨ve macaques showed
an early increase of the chemokine CXCL11 at 24 h.p.i. (Po0.01).
In contrast, DENV-immune macaques showed a decrease of
CXCL11 by day 10 p.i. (Po0.01) compared to baseline levels with
a trend to have a sustained lower level by day 15 p.i. (Fig. 8c).
ILR1-a was also increased at 24 and 48 h.p.i. (Po0.01) and
by days 8 and 15 p.i. (Po0.05) in the naı¨ve but not in the
DENV-immune cohort. Only one macaque pre-exposed to
DENV-2 (BS02) showed a transient increase in the levels of
this cytokine (Fig. 8d). The T cell-activating chemokine CXCL10
was elevated in both groups at 24 h.p.i., with a significant high
in naı¨ve macaques (Po0.01) and a distinct increase in
DENV-immune cohort (Po0.05). Thereafter CXCL10 remained
high only in naı¨ve macaques at 4 and 6 days p.i. (Po0.05)
(Fig. 8e). The B-cell-attracting chemokine-1 CXCL13 (BAL) level
was highly variable in all four macaques in DENV-immune
cohort (Fig. 8f). For the naı¨ve cohort, this chemokine showed a
slow increase p.i reaching higher levels on days 4 (Po0.05), 6
(Po0.01), 8 and 10 p.i. (Po0.05 at both time points). B
cell-activating factor (BAFF) was abundantly produced in all
except in one animal (6N1) in the naı¨ve cohort from 24 h.p.i.
through 30 d.p.i. However, because of the lack of BAFF secretion
by that animal the values did not reach statistically significant
difference compared to baseline levels. DENV-immune cohort
showed small peaks at 48 h.p.i. and by day 30 p.i. but values were
not statistically relevant compared to their basal levels (Fig. 8g).
Finally, level of cytolitic protein perforin increased p.i. in the
DENV-immune cohort reaching statistically significant difference
by 48 h.p.i. (Po0.05), and maintained until 6 d.p.i. (Po0.05). By
days 8–30 p.i., values declined gradually (Fig. 8h). Naı¨ve cohort
produced variable levels of perforin; two macaques with high and
two macaques with low levels but without significant difference
compared to their baseline levels (Fig. 8h).
Discussion
This proof-of-concept study is to advance the knowledge of the
role of pre-existing flaviviral Abs during a ZIKV infection. Early
work by Halstead et al. showed that after a secondary DENV
infection viremia increased in non-human primates, suggesting
that ADE may increase viral load through cross-reactive Abs.
This was a limited study in macaques and only a trend was
reported without showing statistically significant differences27,28.
Despite that fact, this report has been used for decades as
supporting evidence for ADE induction after heterologous DENV
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infection in monkeys. The concept of ADE of ZIKV after DENV
infection was further reinforced by recent works that showed the
ability of DENV-immune serum from humans and macaques to
amplify ZIKV in vitro assay15–17. However, in vitro ADE assays
using laboratory cell lines are notoriously promiscuous and
demonstrate no correlation with disease risk. For example,
DENV-immune sera will enhance even the homotypic serotype
responsible for a past infection if the serum is diluted to
sub-neutralzing concentrations29. In cell culture assays, immune
sera from patients exposed to a variety of different flaviviruses
including yellow fever and Japanese encephalitis viruses will
enhance the infection of DENV30. In this study we have evaluated
the potential of DENV-immune sera to enhance ZIKV using non-
human primates, which are known to be natural hosts of both
viruses. We show that the long-term pre-exposure to DENV
serotypes 1 or 2 induces ADE of ZIKV in vitro, but the in vitro
enhancing antibodies did not increase viremia and disease when
the macaques were challenged with ZIKV. Indeed, previous
exposure to DENV tends to shorten ZIKV viremia. This observed
trend of faster clearance of ZIKV by pre-existing dengue
immunity was similar to that seen in some dengue patients
after secondary infection, in which the DENV was cleared
off fast31. In addition, we show here that previous exposure to
DENV may result in modulation of the immune response
induced by ZIKV without resulting in enhancement of ZIKV
pathogenesis.
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A recent study has demonstrated that immune sera from
people exposed to DENV and West Nile virus can enhance ZIKV
disease in Stat2 / deficient mice15. We urge caution in using
immune deficient mouse models to understand the pathogenesis
of ZIKV in people. Both DENV and ZIKV are primate viruses
that are severely restricted by the mouse type I interferon
responses32. It is well established that in some DENV infection
models, mice develop severe neurological complications and
paralysis, which are rarely observed in people12. The threshold for
antibody mediated disease in mouse models is low and antibodies
have been shown to alter or enhance diseases caused by dengue,
West Nile, yellow fever and Japanese encephalitis viruses in
different mouse models12,33,34. Other than for DENVs, there is no
evidence for antibodies enhancing human diseases caused by
West Nile, Yellow Fever or Japanese encephalitis viruses. With
respect to flaviviruses, mouse models must be judiciously used to
understand well-established human phenotypes.
Previous studies have shown that the time interval
between consecutive DENV infections influence inapparent
versus symptomatic and severe outcome24,25. It has also been
suggested that the window of cross-protection induced by a first
infection with DENV against a second symptomatic infection is
B1–2 years24,25. A strength of our study is that macaques were
challenged with ZIKV at 2.8 years after DENV infection when
transient cross-protection is unlikely to confound the study.
The immunological characterization of the macaques used for
this study is also in agreement with results observed in human
populations showing that ZIKV infection in flavivirus-naı¨ve
subjects induces only low or no NAbs to other flavivirus including
DENV16,35,36. However when ZIKV infection occurs in subjects
previously exposed to other flavivirus, their samples show an
expanded profile of neutralization against different flaviviruses35,37.
In subjects with previous immunity to DENV, we show that ZIKV
infection can induce a transient fourfold expansion of the Nab
titres against DENV after 30 days resembling a secondary DENV
infection38. Of interest is that after ZIKV infection, naı¨ve macaques
showed a significant increase of NAbs against DENV-4 and
DENV-2, but not to the closely related DENV-1 or DENV-3 30
d.p.i. At 60 days after the infection macaques in that cohort still
had NAb titres against DENV-2 and DENV4. Additional
experiments including a cohort previously exposed to DENV4
and specific epitopes characterization are needed to confirm the
in vivo meaning of these findings.
Previous results showed that Abs to NS1 obtained from
memory LYM from ZIKV-infected patients were largely
ZIKV-specific39. In contrast, one particular observation from
our work is that the macaques previously exposed to DENV-2
but not to DENV-1, showed serological cross reactivity with
ZIKV-NS1 as early as 30 d.p.i. of DENV. This cross-reactivity was
still present in 75% of the macaques when tested 2.5 years.p.i.
The region 172–352 of ZIKV-NS1 protein has been shown to
be structurally similar to the NS1 structures of DENV-1 and
DENV-2, and the central region of their loop surfaces have amino
acid sequence identities of 53–56% (ref. 40). NS1 of DENV-1 and
DENV-2 both display a positively charged surface, while NS1 of
ZIKV exhibits a composite platform containing both a positively
and a negatively charged central region40. Because the loop
surface has been suggested to play a crucial role in the
interactions of secreted NS1 with Abs41, the cross reacting Abs
of macaques pre-exposed to DENV-2 may be directed against this
region. Another plausible explanation is that the macaques
previously exposed to DENV-2, in spite of being challenged with
the same amount of inoculum, had significantly more viremia
days when compared to the group exposed to DENV-1, allowing
for a prolonged exposure to DENV-2 NS1 protein
(Supplementary Table 3, Supplementary Methods).
The detection of ZIKV viremia in the presence of existing
DENV NAbs indicates that, in spite of the close relationship
between ZIKV and DENV phylogenetically35 and at structural
level4, both viruses are antigenically distant. Previously, we
reported a strong negative correlation between pre-challenged
Neut50 DENV titres and duration of viremia in macaques
challenged with DENV after being exposed to different DENV
vaccine formulations. Although some macaques with Neut50
titres 420 showed breakthrough viremia (23, 24.4, 5.5 and 28%
after DENV-1, 2, 3 and 4 challenge, respectively) the viremia was
shorter11. Furthermore, it has been shown in rhesus macaques
that the serum IgG profiles and neutralization titres demonstrate
that non-neutralizing, pan-reactive, and serotype-specific NAbs
persist for over a year in DENV-infected macaques42. In this
work we are reporting that 100% of the macaques with DENV
103
102
101
103
102
101
100
103
102
101
100
102
101
10010–1
103
104
102
101
100
100
10–1
102
101
100
10–110–2
Days after ZIKV infection
0 1 2 4 6
IFN-α
CXCL11
CXCL10
BAFF Perforin
CXCL13
IL1-Ra
IFN-γ
DENV-immune
Naïve
8 10 15 30
Days after ZIKV infection
0 1 2 4 6 8 10 15 30
Days after ZIKV infection
0 1 2 4 6 8 10 15 30
Days after ZIKV infection
0 1 2 4 6 8 10 15 30
Days after ZIKV infection
0 1 2 4 6 8 10 15 30
Days after ZIKV infection
0 1 2 4 6 8 10 15 30
Days after ZIKV infection
0 1 2 4 6 8 10 15 30
Days after ZIKV infection
0 1 2 4 6 8 10 15 30
pg
 m
l–1
pg
 m
l–1
pg
 m
l–1
pg
 m
l–1
pg
 m
l–1
103
104
102
101
pg
 m
l–1
103
100
102
101p
g 
m
l–1
pg
 m
l–1
a b
c d
e f
g h
Figure 8 | Previous exposure to DENV modulates the cytokine and
chemokine profiles after ZIKV infection. (a–h) Profiles of marked
cytokines and chemokines after ZIKV infection of DENV-immune and naı¨ve
cohorts are depicted logarithmically in pgml 1. Mean values are shown in
orange and black lines for DENV-immune and naı¨ve cohorts, respectively.
Comparison of the levels of cytokines and chemokines within cohorts
related to their own baseline values or among cohorts was performed using
a two-tailed unpaired t-test with Sidak–Bonferroni correction. Black circles
represent individual naı¨ve macaques, and blue and magenta squares
represent macaques previously exposed to either DENV-1 or DENV-2,
respectively. Dotted lines indicate the threshold of detection for each assay.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15674 ARTICLE
NATURE COMMUNICATIONS | 8:15674 | DOI: 10.1038/ncomms15674 |www.nature.com/naturecommunications 9
NAb titres of 1:160 or higher had ZIKV viremia and that the
magnitude of that viremia did not correlate with the pre-existing
DENV NAb titres. This confirms that in DENV convalescent
subjects, cross-reacting Abs that are able to enhance ZIKV but
neutralize DENV in vitro are present. However, those Abs neither
have the quality to increase and extend the duration of viremia
nor to abrogate ZIKV replication in vivo, even though the viremia
tends to be shorter in the presence of dengue immunity.
Considering published data on the role of IFN-a in the
induction of BAFF43,44 the early production of BAFF observed in
the naı¨ve cohort after ZIKV infection is noteworthy when
compared to the high statistically significant production of IFN-a.
These results suggest the power of ZIKV to induce the innate
immune response by triggering the cell pattern recognition
receptors, which detect pathogen-associated molecular patterns.
Previously, it was confirmed that ZIKV has the capability similar
to DENV to activate the Toll-Like Receptor 3 (TLR3) pathway in
human organoids and skin cells45,46.
CXCL13 is a recognized biomarker for the activity of Follicular
B helper T cells (Tfh). Plasma levels of CXCL13 strongly correlate
with germinal centers (GC) Tfh-cell frequencies in draining
lymph nodes after specific immunization in rhesus macaques47.
These cells play a critical role in mediating the selection and
survival of B cells capable of producing high-affinity Abs against
foreign antigens, and also memory B cells capable of quick
immune re-activation in the future if ever the same antigen, or
related, is re-encountered48. Our results show a positive
correlation among CD20þ /CD69þ B cells and serum levels of
CXCL13 in 75% of macaques previously exposed to DENV
and having a secondary exposure to a closely related virus
(ZIKV). On the other hand, 100% of the naı¨ve macaques
experiencing a first exposure to a flavivirus show statistically
higher significant level of CXCL13 compared to their own basal
levels. These results are confirmatory on the potential value of
CXCL13 as a biological marker of GC activity and B cells
activation after a primary or a secondary viral infection, in this
case related to ZIKV49. Additional studies with large cohorts of
NHP and humans are guaranteed to advance this concept.
Immune profiling of the memory CD4þ and CD8þ T-cell
responses in the naı¨ve and DENV-immune macaques revealed no
defects in the ability of the DENV-immune cohort to respond to
ZIKV infection. Notably, the DENV-1 immune animal BS14,
had a strong polyfunctional CD4þ and CD8þ T with detectable
IFN-g and TNF-a production and a strong CD107a staining
when stimulated with the ZIKV E-peptide pool, revealing that the
prior DENV infection did not inhibit the ability of these
macaques to support a robust response to ZIKV. We also noted
that the DENV-immune macaques appeared to have higher
percentage of CD107aþ CD8þ T cells in response to stimuli as
compared to the naı¨ve macaques, suggesting that rather than
hampering the immune response, a prior DENV infection
enhanced the ability of the CD8þ T cells to release lytic granules
in response to their cognate antigen. Further studies are needed to
determine if this occurs with pre-exposure to other flaviviruses.
These findings are of utmost relevance for designing ZIKV
vaccines.
Resembling ZIKV infection in humans49, ZIKV-infected
macaques showed mild laboratory abnormal changes. However,
we found that the variation in the absolute number and percent of
LYM is more limited after ZIKV infection that has been reported
after DENV infection42. Also of interest is the increase in liver
enzymes in all ZIKV-infected macaques with a profile very
similar to that reported for DENV-infected macaques42.
However, we find that previous exposure to DENV results in a
modest increase of the liver enzymes after ZIKV infection, which
may suggest a protective role in liver inflammation induced by
ZIKV infection. Further studies are needed to understand the
immune mechanism behind this finding.
The skin rash reported in one animal previously exposed
to DENV-1 (BS14) remains inconclusive, as presence of the
virus was not detected by RT-PCR in skin biopsy (Supplementary
Note 1, Supplementary Table 4). The histopathology of the
skin consisting of minimal amounts of non-specific lymphoplas-
macytic infiltrates within the superficial dermis is similar to
findings described in humans which have developed cutaneous
erythematous lesions50. However, we consider that there is
limited scientific value to a single incidence of rash.
Previous exposure to other flavivirus has been speculated to
contribute to the ZIKV-associated microcephaly cases in South
America, because DENV is endemic in this population. It would
be interesting to know whether ADE predisposes utero infection
and congenital malformations. Although that is not the focus
of this study, our results provide valuable clues that the
pre-existence of a long-term immune response to DENV neither
enhances the peak of ZIKV viremia nor impairs the course of its
infection. In addition, we show that the pre-existing immunity to
DENV tends to modulate the innate, humoral and T-cell immune
responses. Because fetal abnormalities have been associated with
prolonged ZIKV viremia51, and more recently, higher viremia has
been linked to invasion of the central nervous system (CNS) in
macaques26, results from our work may suggest that pregnant
women with previous exposure to DENV may have limited ZIKV
viremia and less tendency to have invasion of CNS. These
inferences invigorate the need for further direct and in-depth
investigations. Our results reinforce the value of NHP model to
understand the complex serological interaction among
flaviviruses and to support the design of effective flavivirus
vaccines.
Methods
Viral stock. ZIKV H/PF/2013 strain, kindly provided by CDC, Dengue Branch,
San Juan, Puerto Rico, was used in this study to provide comparative results with
previously published data52. This ZIKV strain is known to replicate well in rhesus
macaques. Virus was expanded and tittered by Plaque Assay and qRT-PCR using
protocols standardized in our laboratories. DENV-1, Western Pacific 74, and
DENV-2, New Guinea 44 strain used to infect macaques in 2013 and strains
DENV-3 Sleman 73, and DENV-4 Dominique used for neutralization assays were
kindly provided by Steve Whitehead (National Institutes of Health, Bethesda,
Maryland).
Immunizations and virus challenges of macaques. Young adult rhesus
macaques (4–5 years of age) seronegative for DENV and ZIKV were housed in the
CPRC facilities, University of Puerto Rico, San Juan, Puerto Rico. All procedures
were reviewed and approved by the Institute’s Animal Care and Use Committee at
Medical Sciences Campus, University of Puerto Rico (IACUC-UPR-MSC), and
performed in a facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC) (Animal Welfare Assurance
number A3421; protocol number, 7890115). In addition, steps were taken to
ameliorate sufferings in accordance with the recommendations of the Weatherall
report on The Use of Nonhuman Primates in Research. For instance, all procedures
were conducted under anaesthesia by intramuscular injection of ketamine at
10–20mg kg 1 of body weight, as approved by the IACUC. Anaesthesia was
delivered in the caudal thigh using a 23-Gauge sterile syringe needle. During the
period of the entire study, the macaques were under the environmental-enrichment
programme of the facility, also approved by the IACUC. Macaques were
continuously monitored by trained veterinarians at the Animal Research Center.
For ZIKV challenge, four macaques previously infected with DENV-1 or 2 serotype
in the year 2013 (Cohort 1) and four naı¨ve macaques (Cohort 2) were sub-
cutaneously injected in the deltoid area with 500 ml of 1 106 p.f.u. of ZIKV
(H/PF/2013 strain) in PBS. Both cohorts were matched in age and sex. All
macaques were male and the average age for cohort 1 was 5.3 years (5.8, 5.8, 4.75
and 4.9 years) and that of cohort 2 was 5.1 years (5.8, 3.9, 5.9 and 4.58 years).
While in quarantine and after ZIKV infection macaques were regularly evaluated
twice daily for evidence of disease or injury. All macaques continued to eat and
drink normally during this period. Weights were taken on baseline and every other
day during the acute infection period (days 1–25), then at day 30 d.p.i.). Rectal and
external temperature were taken daily during the acute infection period (days
1–25) and on day 30 p.i. External temperature was recorded by using an infrared
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device (EXTECH Instruments, Waltham, MA). Since the macaques were already
anesthetized, the infrared thermometer could be positioned close to the forehead,
allowing accurate readings and constant positioning of the IR thermometer directly
to the animal’s forehead at a close range (within 20) as per the manufacturer’s
instructions.
In vitro ADE assay in K562 cells. The ability of serum Abs to enhance ZIKV
virus infection in K562 cells (ATCC CCL-243) was carried out with a protocol that
was previously described for DENV ADE29 with some modifications. Briefly,
macaque serum was diluted fourfold starting after an initial dilution of 1:10, and
then incubated with ZIKV virus (strain H/FP/2013 grown in Aedes albopictus cells,
clone C6/36 ATCC CRL-1660) at a multiplicity of infection (MOI) of 1.0 for 1 h at
37 C. Approximately 5 104 cells were added to each well in a 96 well-plate
containing the mixture of the virus and the Abs. After incubation at 37 C for 2 h,
cells were washed with fresh media twice and incubated at 37 C for 22 h. Cells
were washed again, fixed with 4% PFA, permeabilized with saponin and
intracellularly stained for ZIKV E protein using monoclonal antibody 4G2
conjugated to Alexa-488 diluted 1:400 (kindly provided by Dr Ralph Baric,
University of North Carolina-Chapel Hill, North Carolina, USA). Per cent
infection was determined by flow cytometry using a Guava flow cytometer.
qRT-PCR. Viral RNA for real-time PCR assay was extracted from 140 ml of virus
isolate (previously tittered by plaque assay) or serum samples using QIAmp Viral
RNA mini kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions.
Real-time RT-PCR (TaqMan) assay-specific primers and probes for ZIKV were
designed by Sigma-Aldrich (St Louis, MO) following the protocol developed by the
Molecular Diagnostics and Research Laboratory Centers for Disease Control and
Prevention, Dengue Branch at San Juan, PR35,53. Primers and probe sequences are
provided in Supplementary Table 5. RNA from other flaviviruses were included as
negative control. For the reaction mixture, 5 ml of RNA was combined with 100 mM
primers and 25 mM probe in a 25 ml total volume using Life Technologies
SuperScriptIII Platinum assay kit (Life Sciences). Assays were performed in an
iCycler iQ Real Time Detection System (Bio Rad, CA). For quantification, a
standard curve was generated from tenfold dilutions of RNA from a known
amount of virus, the titre of which was determined by plaque assay as previously
described54–56.
ELISA for DENV and ZIKV. Before conducting ZIKV infection studies, we
characterized the macaques’ immune response against DENV and ZIKV. For this
study, we used acute and convalescent samples (1 and 2.5 years after DENV
infection) collected from all macaques infected with DENV-1 (n¼ 4) or DENV-2
(n¼ 4) 2.8 years before ZIKV infection. From all four DENV-infected macaques
we selected two macaques per serotype to expose to ZIKV. Seroreactivity to DENV
was tested using commercial IgG and IgM ELISA kits (Focus, Cypress, CA). Anti
ZIKV-NS1 IgG was examined using a commercial kit (Alpha Diagnostic, San
Antonio, TX), and ZIKV IgM was assessed with an available commercial kit
(InBios, Seatle, WA).
DENV and ZIKV titration and FRNT60/PRNT60. Assay was performed by
seeding Vero81 cells (ATCC CCL-81) (B8.5 104 per well) in 24 well plates with
DMEM (Dulbecco’s Modified Eagle’s medium, Thermo Fisher Scientific). The next
day tenfold dilution of the virus was made in diluent medium (Opti-MEM
(Invitrogen) with 2% FBS (Gibco) and 1% antibiotic/antimycotic (HyClone).
Prior to inoculation, growth medium was removed and the cells were inoculated
with 100 ml per well of each dilution in triplicates, and the plates were incubated
1 h/37C/5%CO2/rocking. After incubation, the viral dilutions were overlaid with
1ml Opti-MEM including 1% Carboxymethylcellulose (Sigma), 2% FBS, 1%
non-essential aminoacids (Gibco), 1% antibiotic/antimycotic (HyClone). After 3–5
days of incubation at 37 C/5%CO2, overlay was removed; the cells were washed
twice with phosphate buffered saline (PBS) and fixed in 80% methanol.
For ZIKV, cells were stained with crystal violet. For DENV, plates were blocked
with 5% non-fat dry milk in PBS and incubated for 1 h per rocking with anti-E
mAb 4G2 and anti-prM mAb 2H2 (kindly provided by Dr Aravinda de Silva), both
diluted 1:250 in blocking buffer. The plates were then washed and incubated 1 h
with horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Sigma),
diluted 1:1,000 in blocking buffer. Foci were developed with TrueBlue HRP
substrate (KPL) and counted. For the Focus/Plaque Reduction Neutralization
Test (FRNT/PRNT), sera were diluted twofold and mixed with B35 focus per
plaque-forming units (FFU per p.f.u. per ml) of virus and then incubated for 1 h at
37 C. Virus-serum dilutions were added to the cells and incubation was continued
for 1 h at 37 C per rocking, and overlay medium was added and processed as
described above. Mean focus diameter was calculated from Z20 foci per clone
measured at  5 magnification. Results were reported as the FRNT or PRNT with
60% or greater reduction in DENV or ZIKV focus or plaques (FRNT60 or
PRNT60); and 1:20 is considered a positive titre, and o1:20 is considered a
negative Neut titre.
Binding assay. For virus capture ELISA assay, Microlon 600 96-well plates (VWR,
Radnor, PA) were coated overnight at 4 C with a mixture of 100 ng of 4G2/2H2
Abs in 0.1ml coating buffer (Sigma, 08058). Unbound Abs were washed off with
PBS containing 0.05% Tween 20, and blocked with 3% BSA (Fisher). Virus was
diluted in blocking buffer to optimal concentrations, and 0.1ml was added to
each well and incubated 1 h at 37 C. Unbound viruses were removed by washing,
and serum samples diluted in blocking buffer were added and incubated for
another hour. Unbound serum was removed by washing and then incubated for 1 h
at 37 C with goat-anti-monkey secondary Ab conjugated with HRP (Fitzgerald,
MA, USA). Unbound secondary Ab was washed off, and signals were developed
with o-phenylenediamine dihydrochloride substrate tablets (Sigma, 34006).
OD was read at 492 nm.
Phenotyping of immune cells. Phenotypic characterization of rhesus
macaque PBMCs was performed by multicolour flow cytometry using direct
immunofluorescence. Aliquots of 150ml of heparin whole blood were directly
incubated with Abs for 20min. at room temperature; red blood cells were lysed
with ACK, and cells were then washed twice with PBS and fixed with 1.6%
methanol-free formaldehyde before analysis in a CyAn LDP (Beckman-Coulter,
USA) flow cytometer. Antibodies used in this study were: CD123w-APC (7G3),
CD3 FITC or v500 (SP34 and SP34.2, respectively), CD4-PerCP-Cy5.5 (L200) and
HLA-DR PerCP-Cy5.5 (G46.6) from BD-Biosciences; CD14-FITC (322A-1 (My4)),
CD159a (NKG2A)-PE (Z199), CD20-FITC (H299(B1)), CD335 (NKp46)-PC7
(BAB281) and CD337 (NKp30)-PC5 (Z25) from Beckman-Coulter; CD11c-PE
(3.9), CD16-Alexa Fluor 700 (3G8) and CD20-APC (2H7) from Biolegend; CD69-
PE (FN50) from DAKO, CD8-Pacific blue (3B5) from Invitrogen; CD66abce-FITC
(TET2) from Miltenyi Biotec. and CD159c (NKG2C)-APC (134522) from R&D
Systems. Information on dilution of Abs is provided in Supplementary Table 6.
For analyses, LYM were gated based on their characteristic forward and side
scatter pattern; T cells were then selected with a second gate on the CD3 positive
population. CD8 T cells were defined as CD8þCD3þ and CD4 T cells were
CD4þCD3þ . Natural Killer cells were defined as CD3CD20CD14 and
analysed by the expression of NK cell markers CD16, CD8, NKG2A, NKG2C,
NKp30 and NKp46. B cells were defined as CD20þCD3CD14 (Supplementary
Table 7). The activation marker CD69 was determined in each different lymphoid
cell population (Supplementary Fig. 5). Monocytes were defined as CD20
CD3CD14þ and CD20CD3CD14þCD16þ . Finally, dendritic cells (DCs)
were separated in two populations by the expression of CD123 (pDCs) or CD11c
(mDCs) in the HLA-DRþ CD3 CD14 CD20 CD66 population.
Cell-immune response assessment. Intracellular cytokine staining of immune
rhesus macaque PBMCs was performed by multicolour flow cytometry using
methods similar to those described by Meyer et al.57. Detailed information of the
used Abs is provided in Supplementary Table 8. Briefly, B1 107 day 30 and day
60 PBMC samples from both the naı¨ve and DENV-immune macaques were
thawed 1 day prior to stimulation. Each sample was aliquoted and 1.5 106
PBMCs were infected overnight with a combination of DENV-1 (WP 74), and
DENV-2 (NGC44) at a MOI of B0.1 or ZIKV at a MOI of 0.5 in RPMI medium
with 5% FBS. The remaining 7 106 PBMCs were rested overnight as described
earlier58 in 5ml of RPMI with 10% FBS. These rested PBMCs were then stimulated
for 6 h at 37 C, 5% CO2 with a-CD3-1 (100 ngml 1), ZIKV-E peptides (15-mers
overlapping by 10 amino acids, 2.5 mgml 1 per peptide), ZIKV-NS1 protein
peptides (15-mers overlapping by 10 amino acids, 475 ngml 1 per peptide), or
DENV-1 and DENV-2 E peptides (1.25 mgml 1), all in the presence of brefeldin A
(10 mgml 1), a-CD107a-FITC (H4A3) (10 ml), and co-stimulated with a-CD28.2
(1 mgml 1) and a-CD49d (1mgml 1). Peptides sequences used on this
experiment are provided as Supplementary Table 9. After stimulation, the
cells were stained for the following markers: CD4-PerCP Cy5.5 (Leu-3A (SK3),
CD8b-Texas Red (2ST8.5H7), CD3-PacBlue (SP34), CD20-BV605 (2H7),
CD95-V510 (DX2), CD28.2-PE-Cy5, IFN-g-APC (B27) and TNF-a-PE-Cy7
(MAB11). The samples were then run on an LSRII (BD) and analysed using Flowjo
(Treesar). Lymphocytes were gated based on their characteristic forward and side
scatter pattern, T cells were selected with a second gate on the CD3-positive
population, and at the same time CD20-positive cells were excluded.
CD8þ T cells were defined as CD3þ CD20 CD8þ and CD4þ T cells as
CD3þ CD20 CD4þ . Cytokine expression was determined by the per cent
CD4þ or CD8þ -positive cells, and then stained positive for the cytokine IFN-g or
TNF-a. CD107a were also measured in these populations to determine functional
cytotoxicity. Further analysis was also performed to examine CD28 and CD95
expression on the LYM populations to study the presence of central and effector
memory cell populations.
Multiplex cytokine analysis of plasma. Rhesus macaques serum samples were
analysed for 32 cytokines and chemokines by Luminex using established protocols
for Old World primates59. Evaluation of analytes B lymphocyte chemoattractant
(BLC, CXCL13), B cell-activating factor (BAFF), eotaxin (CCL11), GRO a
(CXCL1), interferon alpha (IFN-a), IFN-g, interleukin-1 beta (IL-1b), IL-1 receptor
antago nist (IL-1RA), IL-2Ra, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-18, IL-22, IL-23,
interferon gamma-induced protein 10 (IP-10, CXCL10), interferon-inducible T-cell
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alpha chemoattractant (I-TAC, CXCL11), monocyte chemoattractant protein 1
(MCP-1, CCL2), macrophage migration inhibitory factor (MIF), macrophage
inflammatory protein 1-alpha (MIP-1a, CCL3), MIP-1b (CCL4), perforin,
regulated on activation, normal T cell expressed and secreted (RANT ES, CCL5),
tumour necrosis factor-alpha (TNF-a TNF-b, and soluble CD40 ligand (sCD40L)
were included in this assay. Only analytes quantifiable above the limit of detection
are presented.
Statistical methods. Statistical analyses were performed using GraphPad Prism
6.0 software (GraphPad Software, San Diego, CA, USA). For viral burden analysis,
the log titres and levels of vRNA were analysed by one-way ANOVA. The statistical
significance between or within groups evaluated at different time points was
determined using two-way analysis of variance (ANOVA) (Bonferroni’s multiple
comparisons test) or unpaired t-test to compare the means. The P values are
expressed in relational terms with the alpha values. The significance threshold for
all analyses was set at 0.05; P values less than 0.01 are expressed as Po0.01.
Data availability. All relevant data are available from the authors upon request.
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